Abstract
The short-term outcome and cost savings of a therapeutic interchange from calcium channel blocker (CCB) monotherapy to a fixed-dose combination of bisoprolol/hydrochlorothiazide (HCTZ) were evaluated. Sixty patients with mild-to-moderate hypertension initiated on and controlled with a single daily dose of amlodipine (n = 20), sustained-release diltiazem hydrochloride (HCl) (n = 20), or nifedipine gastrointestinal therapeutic system (GITS) (n = 20) were switched to bisoprolol/HCTZ. At the end of 3 months of follow-up after the switch, 55 of 60 (92%) patients maintained blood pressure control without dose-limiting side effects on the combination product. Mean blood pressure during CCB and bisoprolol/HCTZ treatment was not significantly different. All five treatment failures on the combination product occurred as a result of a loss of blood pressure control. Side effects were reported in 42% of patients on CCB therapy compared with 10% of bisoprolol/HCTZ therapy (P = 0.02). The cost analysis indicated that acquisition cost of the drugs was $16,868 less per year for bisoprolol/HCTZ than for CCBs. The savings were reduced by $11,724 as a result of clinic visits, laboratory testing, and side-effect management costs associated with the switch.
| Original language | English |
|---|---|
| Pages (from-to) | 563-569 |
| Number of pages | 7 |
| Journal | P and T |
| Volume | 23 |
| Issue number | 11 |
| State | Published - 1998 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pharmacology
Cite this
Cost savings associated with therapeutic interchange in the treatment of mild-to-moderate hypertension. / Hilleman, Daniel E.; Wadibia, E. C.; Lucas B.D., Jr.
In: P and T, Vol. 23, No. 11, 1998, p. 563-569.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cost savings associated with therapeutic interchange in the treatment of mild-to-moderate hypertension
AU - Hilleman, Daniel E.
AU - Wadibia, E. C.
AU - Lucas B.D., Jr
PY - 1998
Y1 - 1998
N2 - The short-term outcome and cost savings of a therapeutic interchange from calcium channel blocker (CCB) monotherapy to a fixed-dose combination of bisoprolol/hydrochlorothiazide (HCTZ) were evaluated. Sixty patients with mild-to-moderate hypertension initiated on and controlled with a single daily dose of amlodipine (n = 20), sustained-release diltiazem hydrochloride (HCl) (n = 20), or nifedipine gastrointestinal therapeutic system (GITS) (n = 20) were switched to bisoprolol/HCTZ. At the end of 3 months of follow-up after the switch, 55 of 60 (92%) patients maintained blood pressure control without dose-limiting side effects on the combination product. Mean blood pressure during CCB and bisoprolol/HCTZ treatment was not significantly different. All five treatment failures on the combination product occurred as a result of a loss of blood pressure control. Side effects were reported in 42% of patients on CCB therapy compared with 10% of bisoprolol/HCTZ therapy (P = 0.02). The cost analysis indicated that acquisition cost of the drugs was $16,868 less per year for bisoprolol/HCTZ than for CCBs. The savings were reduced by $11,724 as a result of clinic visits, laboratory testing, and side-effect management costs associated with the switch.
AB - The short-term outcome and cost savings of a therapeutic interchange from calcium channel blocker (CCB) monotherapy to a fixed-dose combination of bisoprolol/hydrochlorothiazide (HCTZ) were evaluated. Sixty patients with mild-to-moderate hypertension initiated on and controlled with a single daily dose of amlodipine (n = 20), sustained-release diltiazem hydrochloride (HCl) (n = 20), or nifedipine gastrointestinal therapeutic system (GITS) (n = 20) were switched to bisoprolol/HCTZ. At the end of 3 months of follow-up after the switch, 55 of 60 (92%) patients maintained blood pressure control without dose-limiting side effects on the combination product. Mean blood pressure during CCB and bisoprolol/HCTZ treatment was not significantly different. All five treatment failures on the combination product occurred as a result of a loss of blood pressure control. Side effects were reported in 42% of patients on CCB therapy compared with 10% of bisoprolol/HCTZ therapy (P = 0.02). The cost analysis indicated that acquisition cost of the drugs was $16,868 less per year for bisoprolol/HCTZ than for CCBs. The savings were reduced by $11,724 as a result of clinic visits, laboratory testing, and side-effect management costs associated with the switch.
UR - http://www.scopus.com/inward/record.url?scp=0032447909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032447909&partnerID=8YFLogxK
M3 - Article
VL - 23
SP - 563
EP - 569
JO - P and T
JF - P and T
SN - 1052-1372
IS - 11
ER -